Roderick B. Meese, M.D., F.A.C.C. - Professional Research

Principal Investigator

• MAGIC II (Stereotaxis) Magnetic assistance in percutaneous coronary interventions vs. conventional interventions
• FLAME (Boston Scientific) The FilterWire EZ system used in the treatment of an acute myocardial infarction for embolic protection protocol
• TROPIC – The does response of Niacin ER/Lovastatin on peak walking time (PWT) in patients with intermittent claudication – a Matrix Design
• PRAISE (Prospective Randomized Amlodipine Survival Evaluation) - A Randomized, Double-blind, Dose-titration, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Amlodipine on Mortality and Morbidity in Patients with Severe Heart Failure
• DUCCS 1 (Duke University Clinical Cardiology Study) – A Randomized Trial of Heparin in Conjunction with Anistreplase in Acute Myocardial Infarction
• DUCCS 2 (Duke University Clinical Cardiology Study 2) – A Randomized Trial of rt-PA (Activase) With Heparin versus APSAC (Eminase) Without Heparin in Acute Myocardial Infarction
• LEXUS with Gas (Losartan Exercise in the United States with Gas Exchange Analysis) – A Multi-center, Double-blind, Randomized, Parallel, Placebo-controlled Study to Investigate the Effects of Losartan on the Exercise Capacity and Clinical Status of Patients with Symptomatic Heart Failure
• PRAISE 2 (Prospective Randomized Amlodipine Survival Evaluation 2) – A Randomized, Placebo-controlled Trial to Evaluate the Effect of Amlodipine on Mortality in Patients with Severe Non-Ischemic Cardiomyopathy
• ELITE II – A Multi-center, Double-blind, Randomized, Parallel, Captopril-controlled Study to Evaluate the Effects of Losartan on Mortality in Patients with Symptomatic Heart Failure
• A to Z – A Multi-center, Randomized, Controlled, Double-blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment with Simvastatin 40 mg Daily for 30 Days Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction with Aspirin
• OVERTURE - Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events
• HERMES – A prospective, non-randomized, multi-center, single-arm clinical trial to assess the safety and efficacy of the Rx Herculink 14 peripheral stent system for treatment of sub-optimal post-procedural percutaneous transkluminal angioplasty (PTA) results in DE NOVO or restenotic renal artery stenoses
• CHESS (Comparative HDL Efficacy and Safety Study) – A Multi-center, Double-blind, Randomized, Parallel, 28-Week Study to Evaluate the Efficacy and Safety of Simvastatin 80 mg/day Versus Atorvastatin 80 mg/day in Patients with Hypercholesterolemia
• PROTECT (TIMI 30) – A randomized trail to evaluate the relative protection against post-PCI microvascular dysfunction and post-PCI ischemia among anti-platelet and anti-thrombotic agents

Sub-Investigator

• EPIC 7E3 – A Study of Chimeric 7E3 Fab in Patients Undergoing High Risk Coronary Angioplasty
• Cardizem CD – The Safety and Efficacy of Cardizem CD for the Treatment of Stable Angina Pectoris
• Integralin versus Aspirin in Unstable Angina – A Randomized, Double-blind Comparative Safety and Efficacy Evaluation (Phase II) of Integrelin versus Aspirin in the Management of Unstable Angina
• HIRULOG – A Comparative Study for the Safety and Efficacy of B68967 with Heparin in Patients with Unstable Angina Undergoing PTCA
• FIRST – A Multi-national, Open, Randomized, Parallel Group Comparison of the Effects of Chronic Flolan Therapy Plus Conventional Therapy to Conventional Therapy Alone on Survival in Patients with Severe Refractory Congestive Hear Failure
• IMPACT I – A Randomized, Double-blind Trial of Integrelin versus Placebo in the Setting of Coronary Angioplasty
• IMPACT II – A Randomized, Double-blind, Efficacy and Safety Evaluation of Two Dosing Regimens of Integrelin versus Placebo for Reducing the Complication of Coronary Angioplasty
• FiB07 – A Randomized, Double-blind Study Comparing the Patency Rate and Safety of Two Different Preparations of IV Eminase (NRL 26921) in Patients with Acute Myocardial Infarction
• RAAMI (Rapid Administration of Alteplase (rt-PA) in Myocardial Infarction) Increased Efficacy of 100 mg of rt-PA with Modified Dosing
• UNSA – A Multi-center, Prospective, Randomized, Placebo-controlled Trial of Activase and Heparin in Patients with Unstable Angina
• ISIS 3 (International Study of Infarct Survival 3) – A Randomized, Double-blind Study Comparing 3 Different Thrombolytic Agents and 2 Different Anticoagulant Regimens with the Final Endpoint of Mortality Reduction
• TIMI 3B – (Thrombolysis in Myocardial Infarction and Unstable Angina) – A Study to Determine If Thrombolytinc Therapy Can Reduce the Incidence of Unstable Angina That Progresses to Myocardial Infarction
• CK ASSAY – A Pilot Study for Evaluation of the Utility of Early Serial CK Levels
• GUSTO (Global Utilization of Streptokinase and t-PA for Occluded coronary Arteries) An International Study - A comparison of the Effect on Survival of Three Different Thrombolytic Regions – The Angiographic Sub-study will determine the relationship of coronary patency and re-occlusion to patient outcome
• GUSTO Pilot Trial – A Safety Trial for Doses of t-PA and Streptokinase Given Simultaneously for Acute Myocardial Infarction
• CARS (Coumadin Aspirin Reinfarction Study) – A Randomized, Double-blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin Plus Aspirin to Aspirin Alone in the Prevention of Re-infarction, Cardiovascular Death, and Stroke in Post-myocardial Patients
• Dofetilide 128 – A Randomized, Double-blind, Parallel, Placebo-controlled Evaluation of Orally Administered Dofetilide in Patients with Symptomatic Paroxysmal Atrial Fibrillation of Flutter
• Dofetilide 128A Extension – A Long-term Extension Double-blind Converting to Open-label
• SPICE (Study of Patients Intolerant of Converting Enzyme Inhibitors) – A Pilot Phase II Trial and Registry of Patients with Class II-IV Heart Failure and Left Ventricular Dysfunction
• APLAUD – A 12 Week, Double-blind, Parallel-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Platelet Aggregation of a Dose Range of SB 214857 When Added to Aspirin in Patients with Myocardial Infarction, Unstable Angina, Transient Ischemic Attack, or Stroke
• SADHART (Sertraline Antidepressant Heart Attack Randomized Trial) – A Randomized, Double-blind, Placebo-controlled Trial of Sertraline for Major Depression After Acute Coronary Syndromes: Myocardial Infarction or Unstable Angina
• Val-HeFT – A Multi-country, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Assess the Effect of Valsartan on Morbidity, Mortality, Signs and Symptoms, and Quality of Life in Patients with Stable, Chronic Congestive Heart Failure (NYHA Class II-IV)
• WIZARD – A Randomized, Double-blind, Placebo-controlled Trial of the Effect of Weekly Azithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposure to C. Pneumoniae
• CAPRICORN – A Multi-national, Multi-center, Randomized, Double-blind, Parallel Group Study to Determine the Effects of Carvedilol on Mortality in Patients with Left Ventricular Dysfunction, With or Without Clinical Evidence of Heart Failure, Post Myocardial Infarction
• GUARDIAN – A Double-blind Trial to Investigate Whether Cariporide Reduces the Combined Incidence of All-cause Mortality and Myocardial Infarction in Patients At Risk of Myocardial Necrosis Due to ACS Related to the Disease Process or to an Interventional Cardiac Procedure
• PARAGON B – A Randomized, Double-blind, Placebo-controlled Study of Lamifiban (R044-9883) in Patients with Unstable Angina/Non Q-Wave Myocardial Infarction
• SPEED (Strategies for Patency Enhancement in the Emergency Department) – A Phase II, Randomized, Open-label, Angiographic Trial Evaluating the Benefit of ReoPro Bolus Plus 12 Hour Infusion With and Without Thrombolytic Therapy for Acute Myocardial Infarction
• ASTRA – A Double-blind, Placebo-controlled, Multi-center Pilot Study to Assess the Safety and ex vivo Platelet Aggregation Response of Intravenous AR-C69931MX in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty, With or Without Intracoronary Stent Placement
• ASTRA (Part 2 Open-label vs Abciximab) - A Multi-center Pilot Study to Assess the Safety and ex vivo Platelet Aggregation Response of Intravenous AR-C69931MX in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty With or Without Intracoronary Stent Placement
• HALT MI – A Phase 2 Safety and Efficacy Study of HU23F2G in Patients with Acute Myocardial Infarction Treated with Direct Angioplasty
• INTRO AMI – A Pilot Phase II Safety and Efficacy Evaluation of Eptifbatide (Integrelin) in Patients Receiving Low Dose and Standard Thrombolytic Therapy (Alteplase) for Acute Myocardial Infarction
• LIMITAMI – A Phase II, Randomized, Double-blind, Placebo-controlled, Multi- center, Angiographic Trial of Safety and Efficacy of rhuMAb CD18 in Acute Myocardial Infarction
• GUSTO IVACS – A Phase III, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of ReoPro â , Given as a Bolus Followed by a 24 or 48 Hour Infusion for the Treatment of Acute Coronary Syndrome Without ST Segment Elevation
• AMISTAD II – A Randomized, Double-Blind, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of Adenosine (Pallacor®, Adenosine Injection) as an Adjunct to Reperfusion Therapy (Thrombolysis of Mechanical Reperfusion) in the Treatment of Acute Anterolateral Myocardial Infarction
• GUSTO IV AMI – A Phase III, Randomized, Open-label Trial Evaluating the Efficacy and Safety of ReoPro® (Abciximab) in Combination with Reduced Dose Retavase â /Rapilysin Ô (Recombinant Plasminogen Activator, Retaplase,r-PA) for the Treatment of Acute Myocardial Infarction
• BRACCO – A Clinical Evaluation to Determine the Optimal Imaging Parameters for Tc-99m Teboroxime in Subjects with Coronary Artery Disease and Subjects with No Evidence of Coronary Artery Disease
• TARGET – A Randomized, Multi-center, Double-blind, Abciximab-controlled Study to Evaluate the Efficacy of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention with Intracoronary Stent Placement
• CREDO – A Double-blind, Randomized Trial of Clopidigrel 300 mg Loading Dose and Aspirin 325 mg Followed by Clopidigrel 75 mg and Aspirin Daily Compared with Placebo Loading Dose and Aspirin 325 mg Followed by Clopidigrel 75 mg and Aspirin Daily for the Prevention of Vascular Events and All-cause Mortality in Patients Undergoing Percutaneous Coronary Intervention
• GOLD – A Prospective, Multi-center, Observational Study Evaluating Platelet Function with the Accumetrics Ultegra-Rapid Platelet Function Assay (RPFA) in Patients Undergoing Coronary Interventions Using Platelet Glycoprotein Iib/IIIa Inhibitors
• POSTIT – Boston Scientific Scimed, Inc. – Post Market Research Study on the NIR Stent and Other Commercially Available Coronary Stents
• BRAVO – Blockade of the GP IIB/IIIa Receptor to Avoid Vascular Occlusion
• CHARM (Candesartan Cilexetil in Heart Failure: Assessment of Reduction in Mortality and Morbidity) – Studies of Candesartan in Patients with Heart Failure Who Are ACE Intolerant and Have Depressed Left Ventricular Systolic Function (0003), Who Are Treated With ACE Inhibitors and Have Depressed Left Ventricular Systolic Function (0006), and Patients with Heart Failure with Preserved Left Ventricular Function (0007)
• VALIANT (Valsartan in Acute Myocardial Infarction) – A Multi-national, Multi-center, Double-blind, Randomized, Active-controlled, Parallel Group Study Comparing the Efficacy and Safety of Long-term Treatment with Valsartan, Captopril, and Their Combination in High-risk After Myocardial Infarction
• RAFT – A Double-blind, Placebo-controlled, Randomized Clinical Trial of Slow Release Propafenone (Rythmol â SR) in the Prevention of Symptomatic Recurrences of Atrial Fibrillation
• SYNERGY – A prospective, randomized, open label, multicenter study in patients presenting with acute coronary syndrome, protocol number SNO.GMA.301
• COMMA – A randomized, double-blind, placebo-controlled study of two intravenous dosing regimens of h5G1.1-scFv in patients with acute myocardial infarction undergoing percutaneous transluminal coronary angioplasty reperfusion therapy
• NOET – A Phase III, Open0label, Single-crossover Study to Confirm the Diagnostic Potential of Intravenously-Administered 99mTcN-NOET to Identify coronary Artery Disease during Exercise and Resting Conditions by using Gated Myocardial SPECT Imaging
• RAPSODY – A multicenter, randomized, double-blind, placebo-controlled dose-ranging, safety and efficacy study of precombinant P-Selectin glycoprotein ligand-Ig (rPSGL-Ig) in combination with thrombolytic therapy in patients with acute myocardial infarction
• REPLACE (Part 1) – Randomized evaluation in percutaneous coronary intervention linking Angiomax to reduced clinical events (TMC-BIV-00-01)
• REPLACE (Part 2) – (TMC-BIV-01-03)
• ADEPT – the advanced elements of pacing trial (ADEPT) A factorial trial of automatic rate modulation and mode-switching in Kappa 400 DDDR recipients
• VICC – Visipaque (Iodixanol) vs. Isovue (Iopamidol) in cardiac catheterization
• SPORTIF V – Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Events in Patients with Atrial Fibrillation
• OCTAVE - Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril
• STELLAR (Statin Therapies for Elevated Lipid Levels Compared Across Rosuvastatin) – A 6-Week, Open-label, Dose-comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Cerivastatin, Pravastatin, and Simvastatin in Subjects with Hypercholesterolemia
• REVERT (Reversal of Ventricular Remodeling with Toprol - XL®) – A Multi-center, Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Effect of Extended Release Metoprolol Succinate (Toprol-XL®) on Cardiac Remodeling in Asymptomatic Heart Failure Patients (NYHA Class I) with Left Ventricular Dysfunction
• SELECT – A Multi-center Prospective Randomized, Double-blinded, Parallel Group Study Comparing the Effects of Lotrel® (5/20mg) to Amlodipine (5mg) and Benazepril (20mg) on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension
• MERCURY II - An Open-label, Randomized, Multi-center, Phase IIIb, Parallel Group Switching Study to Compare Atorvastatin and Simvastatin with Rosuvastatin in High Risk Patients with Typer IIa and IIb Hypercholesterolemia
• ExTRACT – TIMI 25 – A randomized, double-blind, double-dummy, parallel group, multinational, clinical study to evaluate the efficacy and safety of Enoxaparin versus unfractionated heparin in patients with acute ST-segment elevation myocardial infarction receiving fibrinolytic therapy
• ICE-IT - A randomized, controlled study of the use of central venous catheter core cooling and rewarming as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction
• MCC-135 - A phase II, double-blind, randomized, exploratory, placebo-controlled study of the efficacy, safety and tolerability of MCC-135 comparing QD vs BID doses in subjects with congestive heart failure, NYHA Class II/III
• ETC-588 - A phase II, randomized, double-blind, placebo-controlled multiple-center pilot study of ETC-588 in patients with acute coronary syndromes (ACS)
• CRESTOR – A 48-Week open-label, non-comparative, multicentre, phase IIIb study to evaluate the efficacy and safety of the lipid-regulating agent Rosuvastatin in the treatment of subjects with Fredrickson Type IIa and Type IIb Dyslipidaemia, including Heterozygous Familial Hypercholesterolaemia (Protocol # 45221L/0091)
• ENLIGHTEN II – A non-randomized evaluation of the 3.5mm and 4.0mm multi-link vision Rx coronary stent system in the treatment of patients with De Novo native coronary artery lesions
• JUMBO (TIMI 26) – A double-blind, randomized, multicetner, dose-ranging trila of CS-747 compared with Clopidogrel in subjects undergoing percutaneous coronary intervention
• VERITAS 1 – Multicenter, double-blind, randomized, placebo-controlled parallel-group to assess the efficacy, safety and tolerability of Tezosentan in patients with acute heart failure
• MICHAELANGELO: OASIS-5 – An international randomized double-blind study evaluating the efficacy and safety of Fondaparinux versus Enoxaparin in the acute treatment of unstable angina / Non ST-segment elevation MI acute coronary syndromes
• CAPTURE – A post-approval study of the Guidant carotid stent systems and embolic protection systems (Carotid Rx Acculink/Accunet Post-Approval trail to uncover unanticipated or rare events)
• ENDEAVOR IV – A randomized, controlled trial of the Medtronic Endeavor drug (ABT-578) eluting coronary stent system versus the Taxus paclitaxel-eluting coronary stent system in De Novo native coronary artery lesions
• TENACITY – A randomized, Multicenter, double-blind, Abciximab-controlled study to evaluate the efficacy of Tirofiban versus Abciximab among subjects undergoing percutaneous coronary intervention with stent placement receiving Bivalirudin or Heparin. Protocol #0120-0401
• EARLY ACS – Early Glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome: A randomized, placebo-controlled trial evaluating the clinical benefits of early front-loaded Eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome
• TIMI 38 – A comparison of (CS-747) and Clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention
• ARRIVE – Taxus peri-approval registry: A two phased, multi-center safety surveillance program
• IMPROVE-IT – A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
• CURRENT / OASIS 7 – Clopidogrel optimal loading dose usage to reduce recurrent events / optimal antiplatelet strategy for interventions
• CHAMPION Platform – A clinical trial comparing treatment with Cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention (Protocol No. TMC-CAN-05-03)
• APPRAISE 1 – A phase 2, placebo-controlled, randomized, double-blind, parallel arm, dose ranging study to evaluate safety and efficacy of Apixaban in patients with recent acute coronary syndrome (protocol CV185023)
• FUSION II – Follow-up Serial Infusions of Natrecor® (nesiritide) for the Management of Patients with Heart Failure